

REPROS THERAPEUTICS INC.

Form 8-K

February 10, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): February 5, 2015

Repros Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-15281

76-0233274

(State or Other

(Commission File (I.R.S. Employer

Jurisdiction of

Number)

Identification No.)

Incorporation)

Edgar Filing: REPROS THERAPEUTICS INC. - Form 8-K

2408 Timberloch Place, Suite B-7
The Woodlands, TX 77380
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (281) 719-3400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- ..Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- ..Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- ..Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
- ..Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c)).

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On February 5, 2015, the Compensation Committee of the Board of Directors of Repros Therapeutics Inc. (the “Company”) approved a grant to Katherine Anderson, the Company’s Chief Financial Officer, of options to purchase 30,000 shares of the Company’s common stock, \$0.001 per share (the “Common Stock”), as compensation for her work in 2014. The options, which were granted under the Company’s 2011 Equity Incentive Plan, have a per share exercise price of \$8.44, the closing price of the Common Stock on the Nasdaq Stock Market on the date of grant, a term of 10 years, and will vest in equal annual installments on the first three anniversaries of the date of grant.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**REPROS
THERAPEUTICS INC.**

By: /s/ Kathi Anderson
Kathi Anderson

CFO

Dated: February 10, 2015